Euroapi SAS (EAPI) - Total Liabilities
Based on the latest financial reports, Euroapi SAS (EAPI) has total liabilities worth €516.70 Million EUR (≈ $604.08 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Euroapi SAS - Total Liabilities Trend (2019–2025)
This chart illustrates how Euroapi SAS's total liabilities have evolved over time, based on quarterly financial data. See EAPI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Euroapi SAS Competitors by Total Liabilities
The table below lists competitors of Euroapi SAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ilex Medical
TA:ILX
|
Israel | ILA286.90 Million |
|
Baiksan
KO:035150
|
Korea | ₩186.04 Billion |
|
Dmc Global Inc
NASDAQ:BOOM
|
USA | $226.13 Million |
|
Sanghi Industries Limited
NSE:SANGHIIND
|
India | Rs33.42 Billion |
|
Carnarvon Energy Ltd
AU:CVN
|
Australia | AU$4.79 Million |
|
Phu Tai JSC
VN:PTB
|
Vietnam | ₫2.89 Trillion |
|
EUROZ Hartleys Group Ltd
AU:EZL
|
Australia | AU$107.40 Million |
|
Fabasoft AG
XETRA:FAA
|
Germany | €64.98 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Euroapi SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Euroapi SAS worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.39 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Euroapi SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Euroapi SAS (2019–2025)
The table below shows the annual total liabilities of Euroapi SAS from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €516.70 Million ≈ $604.08 Million |
+2.11% |
| 2024-12-31 | €506.00 Million ≈ $591.57 Million |
-26.10% |
| 2023-12-31 | €684.70 Million ≈ $800.49 Million |
+9.39% |
| 2022-12-31 | €625.90 Million ≈ $731.74 Million |
+3.11% |
| 2021-12-31 | €607.00 Million ≈ $709.65 Million |
-0.75% |
| 2020-12-31 | €611.60 Million ≈ $715.02 Million |
+9.49% |
| 2019-12-31 | €558.60 Million ≈ $653.06 Million |
-- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry;… Read more